- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01276808
Magnetic Navigation for Contrast and Radiation Reduction (MAGNA)
Reduction in Contrast Volume and Radiation With Magnetic Navigation: a Prospective Randomised Trial
Rationale: Magnetic navigation in complex lesions/vessels may result in reduced contrast and irradiation for patients undergoing percutaneous coronary intervention. The investigators aim to compare the use of the 2 techniques.
Objective: To compare the use of contrast and irradiation used in magnetically navigated PCI (MPCI) with conventional guidewire PCI (CPCI) in patients with complex anatomy (as defined by a clinical prediction rule).
Study design: Prospective randomised controlled, single-blind trial Study population: Healthy human volunteers aged 18 to 80 years of age Intervention (if applicable): One group has the placement of the angioplasty wire with magnetic navigation and the other has the angioplasty wire placed by conventional technique. All other interventions will be performed as per routine practice.
Main study parameters/endpoints:
Primary endpoint The primary endpoint is the amount of contrast used.
Secondary endpoints
- Contrast needed to cross a lesion
- procedural time
- radiation exposure
- Clinical complications at 1 and 12 months
- procedural success
Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
The index procedure is performed as per normal routine and includes history and examination. A blood test will be taken once vascular access has been obtained. After the procedure a questionnaire will be filled in. The patient will have a blood test 2 to 3 days after the procedure, telephone follow-up will occur at 1 and 6 months and a further outpatient visit with ECG will be planned for a year after the index procedure. No additional significant physical or psychological discomfort is expected with participation in the study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The Stereotaxis Niobe® magnetic navigation system received regulatory approval for human clinical use for interventional cardiology in 2003.
Magnetic navigation gives 3 dimensional (3D) directional control over the guide-wire tip during percutaneous coronary intervention (PCI) procedures.
Magnetic navigation has been shown to be feasible and effective (1-3), case reports suggest that it enables the performance of procedures that could not be successfully finished conventionally (4-6), and that the use of the system may lead to reductions in contrast use and procedure time (7-11) that can be expected to result in better patient outcomes, and an economical advantage (less consumables per procedure, more procedures per session). There are only a few centers that perform magnetic navigation for percutaneous coronary intervention The OLVG has performed the most procedures of any of these centers and has included all the patients in a registry.
The registry at the OLVG suggests that different subgroups derive different benefit.
Distal lesions (10) defined as lesions more distal than the first 2 coronary segments from the aorta (thus RCA segment, mid LAD or distal Cx).
Technical success did not differ significantly between magnetic and conventional PCI (88.5 vs 96.2%; p=0.14). Significantly shorter procedural and fluoroscopy time were observed for magnetic compared to conventional PCI (29.9±17.1 vs 42.9±21.1 min, p<0.001; 8.2±7.7 vs 16.7±22.4 min, p=0.01 respectively). More contrast was used in de conventional PCI group (54 ml/patient; P=0.02). These advantages resulted in a mean saving of 1652 euro per patient (P<0.0001).
Primary PCI (11) The technical success rate was high in both the MPCI and CPCI groups (95.4% vs 98%; P = NS). There was significantly less contrast usage in the MPCI compared to the CPCI group (167±80/patient vs 220±87/patient; P<0.001). Procedural times were not significantly different for MPCI compared to CPCI (30.8±16.5 min vs 33.6±15.8 min, p=0.2) while fluoroscopy times were significantly better (8.1±5.0 min vs 14.6±26.5 min, p<0.05).
Simple lesions (8) as defined by the elective treatment of a single discrete stenosis that would require a maximum of two stents and excluding multiple lesions in the target vessel, multi-vessel PCI, bifurcation lesions, acute and chronic total occlusions, or a previous failed conventional attempt for the same target lesion.
Procedural and fluoroscopy times were not significantly different for MPCI compared to CPCI (21.0±14.5 min vs 24.7±14.0 min; 4.9±4.8 min vs 7.3±10.3 min, p=NS). There was a significant reduction in median contrast use (60 ml/patient [41-100] vs 100 ml/patient [64-130]; P=0.006).
Summary Benefit appears to increase depending on the complexity of the vessel/lesion with distal lesions showing a significant benefit in terms of contrast use, procedure time and fluoroscopy time.
Simple lesions show that procedures are not negatively influenced in terms of time, or irradiation and there may be benefit in terms of contrast use.
Acute procedures where time is at a premium (primary PCI for a heart attack) are not slowed by the use of the system.
Furthermore, the investigators have published a clinical prediction rule for selection of patients that will most benefit from this technology. (12)
The use of this system may have a number of benefits
- Reduction in the procedure time, irradiation and contrast use in the patient
- Better procedures with wire passage that maintains the tip coaxial in the vessel to avoid inadvertent sidebranch cannulation or more accurate bend/sidebranch entry to produce less complications
The hypothesis that MPCI is better than CPCI should be investigated by a randomized controlled trial (Magnetic navigation wire placement vs conventional wire placement).
The investigators plan to randomize patients into magnetic and conventional groups.
Endpoints:
- Primary endpoint Contrast use
Secondary:
Short-term procedural Procedure Fluoroscopy Procedure time Procedure success Short term contrast nephropathy
- Long-term MACCE at 1 month and 12 months.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
N Holland
-
Amsterdam, N Holland, Netherlands, 1091 AC
- Recruiting
- Onze Lieve Vrouwe Gasthuis
-
Contact:
- Mark S Patterson, PhD
- Phone Number: 020 5993440
- Email: dr.markspatterson@gmail.com
-
Principal Investigator:
- Mark S Patterson, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age>18 years
- Elective presentation for PCI, This implies that the coronary anatomy is known and can be analysed according to the clinical prediction rule.(13)
- The included patients must have a calculated formula with a result equal or greater than 6.
Pct=1*Vb+1*(Vl=1)+2*(Vl=2)+2*Vc+1*Lbb)+1*(Ll=1)+2*(Ll=2)
Pct - Predicted crossing time (prolonged if integer ≥ 6). Vb - Number of bends before the lesion. Each bend causes deformation of the wire resulting in friction. A greater number of bends leads to increased friction resulting in more difficultly in manipulating the wire.
Vl - End-to-end length from the ostium to the lesion. The more distal the lesion is from the ostium, then the greater the chance of encountering problematic bends that impair manipulation, and also the longer the time required to physically pass the wire. This is divided into shorter than 50 mm (=0), between 50 and 100 mm (=1) and greater then 100 mm (=2).
Vc - Vessel calcification. Calcium may increase friction as the vessel becomes more rigid and less deformable and does not conform to the wire. The frictive effect of a specific angle will be accentuated if deformation cannot occur.
Lbb - Side-branches within 10 mm. Side-branches within 10 mm of the lesion increase difficultly because, on the approach to a lesion finer control is necessary, the fixed wire-tip angle needed for bends now may have more of a predisposition for side-branches.
Ll - Lesion length. Longer lesions produce more friction on the wire. The detailed analysis of 3D reconstruction by the Paeion system has been described earlier.(12) This rule was tested on a validation group taken from a second cohort of 415 lesions. The c-statistic derived from this group was 0.82 showing good discrimination.
- Patients can be admitted from the lounge, the ward or the CCU
- Diagnostic coronary angiography films suitable for 3D reconstruction Informed consent obtained.
Exclusion Criteria:
- Active bleeding
- Cardiogenic shock
- Resuscitation / intubation
- Cerebrovascular accident within 30 days
- Major bleeding within 30 days according to the TIMI definitions
- Severe hypertension (>180/110) after medical treatment
- Relevant trauma or surgery within 6 weeks
- Active peptic ulcer within 3 months
- Hemorrhagic retinopathy
- Thrombocytopenia (<150)
- Severe renal dysfunction (Creatinine >140)
- Ongoing or desired use of GpIIb/IIIa blockers
- Participation in another clinical study
- Women who are pregnant or women who are breast-feeding. Inability to follow the patient (e.g. foreign or long-distance patients on holiday)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Magnetic navigation PCI
These patients will be treated with magnetically navigated percutaneous coronary intervention
|
Magnetically navigated angioplasty wire technique
Other Names:
|
|
Active Comparator: Conventional PCI
These patients will be treated with normal standard percutaneous coronary intervention
|
Conventional manual angioplasty wire percutaneous coronary intervention
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Total procedural contrast fluid use
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Short-term procedural success
Time Frame: 1 year
|
1 year
|
|
Procedure Fluoroscopy
Time Frame: 1 year
|
1 year
|
|
Procedure time
Time Frame: 1 year
|
1 year
|
|
Short term contrast nephropathy
Time Frame: 1 year
|
1 year
|
|
MACCE at 1 month and 12 months
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mark S Patterson, PhD, Onze Lieve Vrouwe Gasthuis
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WO nummer R-10.420
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Infirmerie Protestante de LyonRecruitingCoronary Artery Bypass | Coronary Artery Disease(CAD) | Off Pump Coronary Artery Bypass Surgery | Hemodynamic Optimization | Hemodynamic Management | Off Pump Coronary Artery Bypass Graft | Coronary Artery Disease With Need for Bypass Surgery | NoradrenalineFrance
-
Shanghai Bluesail Boyuan Medical Technology Co....Not yet recruitingCoronary Artery Disease | Coronary Artery Calcification | Severe Coronary Artery DiseaseChina
-
Scitech Produtos Medicos SANot yet recruitingCoronary Artery Disease (CAD) | Multivessel Coronary Artery Disease | Complex Coronary Lesions | Calcific Coronary Arteriosclerosis | Small Vessel Ischemic Disease | Stenosis CoronaryBrazil
-
Istanbul Mehmet Akif Ersoy Educational and Training...Bakirkoy Dr. Sadi Konuk Research and Training Hospital; Ege University; Istanbul... and other collaboratorsActive, not recruitingCoronary Artery Disease (CAD) | Coronary Bifurcation Lesion | Left Main Coronary Artery StenosisTurkey (Türkiye)
-
EBI Anti Sepsis BVCR2O B.V.Not yet recruitingCoronary Artery Disease (CAD) | Coronary Artery Bypass Graft Surgery(CABG)United States, Netherlands, Belgium, United Kingdom
-
I.R.C.C.S Ospedale Galeazzi-Sant'AmbrogioCompletedCoronary Artery Disease (CAD) | Atherosclerosis of Coronary ArteryItaly
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
University Medical Centre LjubljanaRecruitingCoronary Artery Disease With Myocardial InfarctionSlovenia
-
Shunmei MedicalNot yet recruitingCalcified Coronary Artery Disease | Coronary Arterial DiseasePoland, France, Spain
-
OPCI Core Laboratories LLCNot yet recruitingCoronary Artery Disease (CAD) | Coronary Calcification | Coronary Calcified Disease | Coronary Calcified NodulesUnited States
Clinical Trials on Magnetic navigation PCI
-
Medical University of ViennaCompletedChronic Total Coronary Occlusion
-
Norwegian University of Science and TechnologySt. Olavs Hospital; SINTEF Health ResearchCompletedAtrial FibrillationNorway
-
Ruijin HospitalUnknown
-
StereotaxisTerminatedTachycardia, VentricularUnited States, Netherlands, Australia, Belgium, Denmark, France, Czechia
-
Taipei Medical University WanFang HospitalMinistry of Health and Welfare, TaiwanNot yet recruitingColorectal Cancer | Colonoscopy
-
University Hospital GoettingenStereotaxisCompleted
-
Shandong Cancer Hospital and InstituteRecruiting
-
Erasmus Medical CenterCompletedAtrial Fibrillation | Catheter AblationNetherlands
-
Shanghai Jiao Tong University School of MedicineCompleted
-
Magnetecs CorporationUnknownTachycardia, Ventricular | Tachycardia, SupraventricularSpain